ABIVAX Société Anonyme (2X10)

Overview

ABIVAX Société Anonyme is at the forefront of biotechnological advancements, focusing its research and development efforts on creating innovative therapeutics that leverage the body's innate regulatory mechanisms. This approach aims at modulating the immune response for patients suffering from chronic inflammatory diseases, a field of high unmet medical need. Incorporated in 2013, and based in Paris, France, this clinical-stage biotechnology company represents a beacon of hope for individuals dealing with debilitating conditions. Its primary drug candidate, obefazimod, currently undergoing Phase 3 clinical trials, showcases ABIVAX's commitment to pioneering treatments. This drug is poised to offer a new therapeutic option for patients with moderately to severely active ulcerative colitis, a severe and chronic autoimmune disease affecting the colon. The company's strategic direction emphasizes innovation, patient well-being, and the pursuit of delivering breakthrough therapies that can significantly improve life quality for patients worldwide.

Products and Services

• Obefazimod (Lead Drug Candidate)

  ABIVAX's flagship therapeutic candidate, obefazimod, is a novel, orally administered small molecule that aims to provide a new treatment paradigm for patients with moderately to severely active ulcerative colitis. By modulating the immune system, obefazimod offers promise in controlling the damaging inflammatory response associated with this chronic disease. Currently in Phase 3 clinical trials, obefazimod represents the culmination of ABIVAX's research into immune system regulation and its application in treating inflammatory and autoimmune diseases.